Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.
| Author | |
|---|---|
| Abstract | :
We assessed the efficacy and safety of once-daily eslicarbazepine acetate in comparison with twice-daily (BID) controlled-release carbamazepine (carbamazepine-CR) monotherapy in newly diagnosed focal epilepsy patients. |
| Year of Publication | :
2018
|
| Journal | :
Epilepsia
|
| Date Published | :
2018
|
| ISSN Number | :
0013-9580
|
| URL | :
http://dx.doi.org/10.1111/epi.13993
|
| DOI | :
10.1111/epi.13993
|
| Short Title | :
Epilepsia
|
| Download citation |